Mark T. Wagner

Minnetronix Medical, Inc. provides design, development, manufacturing, commercialization services to the electronics-based medical device and life science marketplaces. The company was founded in 1996 and is headquartered in St. Paul, MN.

Sonex Health LLC develops and manufactures surgical device designed to minimize surgical trauma for carpal tunnel release patients. The company was founded by Darryl Bares, Jay Smith and Aaron Keenan in 2014 and is headquartered in Eagan, MN.

The American company is devoted to ushering in a new era of precision medicine in acute care. Prenosis' immunix™ precision diagnostics and evidence generation platform leverages machine learning algorithms trained on deep biological data and broad clinical data designed to capture and illuminate the complex health states of patients more holistically. The company's proprietary dataset is one of the largest and fastest-growing hybrid biomarker-clinical datasets for sepsis care. Prenosis enables physicians, providers, payers, and pharma to understand patients' unique biology and see people differently. The company was founded by Bobby Reddy and Rashid Bashir, and Bobby Reddy has been the CEO since incorporation.

Celleration, Inc. manufactured medical devices. It developed and marketed a proprietary technology to accelerate healing in wounds by delivering therapeutic, low frequency ultrasound without direct contact of the delivery device to the wound surface. The firm’s core product was the MIST Therapy System, impacted all critical aspects of the wound healing process providing clinical and economic benefits to institutions treating nonresponding wounds. The company was founded by Gene Berghoff, Dennis L. Davey and Eliaz P. Babaev in 1999 and was headquartered in Eden Prairie, MN.

Orasi Medical, Inc. is a privately held, early stage medical device company engaged in the development and commercialization of technology to diagnose and monitor neurological diseases. They have developed a painless, non-invasive test that takes less than ten (10) minutes to administer and, based on the results of its current research, is more accurate than current clinical practice. Initially, its aim is to develop the first FDA cleared test for the diagnosis of Alzheimer's disease. In addition, they are developing products for pharmaceutical companies to measure treatment effect and reduce the cost of clinical drug trials for neurological diseases. Ultimately, its long-term goal is to set the standard of care for diagnosis and monitoring of major neurological diseases such as Alzheimer's disease, multiple sclerosis, Parkinson's, autism, depression and attention deficit hyperactivity disorder (ADHD).

VitalMedix, Inc., is a Minneapolis-based, development-stage company that has developed a proprietary, rapidly deployable formulation called Tamiasyn that will potentially allow the human body to endure severe blood loss for an extended period of time and also inhibit human organ damage during the resuscitation process. VitalMedix intends to market Tamiasyn in combination with a hemorrhagic shock treatment system named O2Rescue. It is hoped that this system will offer first responders, trauma center surgeons and military medics a simple, safe and reliable product for preventing serious organ damage and death among victims of severe blood loss. It is believed that Tamiasyn might also have potential applications during invasive surgery and organ preservation, and in cases of stroke. Since 2005, the research conducted by VitalMedix has been funded by the Defense Advanced Research Projects Agency (DARPA). Much of this research has been conducted at the University of Minnesota, which is a shareholder in VitalMedix, Inc. The company now holds an exclusive, global license from the University of Minnesota for Tamiasyn. In order for human trials to begin, the Company will need to have an approved Investigational New Drug [IND] application on file with FDA. The IND provides a compilation of all R&D conducted to date including formulation development, animal pharmacology and toxicology, and supportive literature. The IND must also include a plan for intended additional animal studies and clinical trials. Typically, the time to market for a viable drug candidate is 8-10 years. However, manufacturers can request 'fast track' designation for their product and indication for use if the product offers potential as a life-saving technology superior to current therapies. If designated, FDA will work closely with the manufacturer and provide expedited review and approval times if appropriate. VitalMedix, Inc. intends to request fast track status for Tamiasyn in hemorrhagic shock.

ProVation Medical, Inc. engages in provision of clinical decision support and procedure documentation solutions. Its products include Provation Apex, Provation MD, Provation Order Sets, Provation Care Plans, and Provation MultiCaregiver. The company was founded by Sean Benson and Daniel Steinberger in 1994 and is headquartered in Minneapolis, MN.